TY - JOUR
T1 - Assessment of the Effectiveness, Socio-Economic Impact and Implementation of a Digital Solution for Patients with Advanced Chronic Diseases
T2 - The ADLIFE Study Protocol
AU - García-Lorenzo, Borja
AU - Gorostiza, Ania
AU - González, Nerea
AU - Larrañaga, Igor
AU - Mateo-Abad, Maider
AU - Ortega-Gil, Ana
AU - Bloemeke, Janika
AU - Groene, Oliver
AU - Vergara, Itziar
AU - Mar, Javier
AU - Lim Choi Keung, Sarah N.
AU - Arvanitis, Theodoros N.
AU - Kaye, Rachelle
AU - Dahary Halevy, Elinor
AU - Nahir, Baraka
AU - Arndt, Fritz
AU - Dichmann Sorknæs, Anne
AU - Juul, Natassia Kamilla
AU - Lilja, Mikael
AU - Sherman, Marie Holm
AU - Laleci Erturkmen, Gokce Banu
AU - Yuksel, Mustafa
AU - Robbins, Tim
AU - Kyrou, Ioannis
AU - Randeva, Harpal
AU - Maguire, Roma
AU - McCann, Lisa
AU - Miller, Morven
AU - Moore, Margaret
AU - Connaghan, John
AU - Fullaondo, Ane
AU - Verdoy, Dolores
AU - de Manuel Keenoy, Esteban
AU - ADLIFE Study Group
PY - 2023/2/10
Y1 - 2023/2/10
N2 - Due to population ageing and medical advances, people with advanced chronic diseases (ACD) live longer. Such patients are even more likely to face either temporary or permanent reduced functional reserve, which typically further increases their healthcare resource use and the burden of care on their caregiver(s). Accordingly, these patients and their caregiver(s) may benefit from integrated supportive care provided via digitally supported interventions. This approach may either maintain or improve their quality of life, increase their independence, and optimize the healthcare resource use from early stages. ADLIFE is an EU-funded project, aiming to improve the quality of life of older people with ACD by providing integrated personalized care via a digitally enabled toolbox. Indeed, the ADLIFE toolbox is a digital solution which provides patients, caregivers, and health professionals with digitally enabled, integrated, and personalized care, supporting clinical decisions, and encouraging independence and self-management. Here we present the protocol of the ADLIFE study, which is designed to provide robust scientific evidence on the assessment of the effectiveness, socio-economic, implementation, and technology acceptance aspects of the ADLIFE intervention compared to the current standard of care (SoC) when applied in real-life settings of seven different pilot sites across six countries. A quasi-experimental trial following a multicenter, non-randomized, non-concurrent, unblinded, and controlled design will be implemented. Patients in the intervention group will receive the ADLIFE intervention, while patients in the control group will receive SoC. The assessment of the ADLIFE intervention will be conducted using a mixed-methods approach.
AB - Due to population ageing and medical advances, people with advanced chronic diseases (ACD) live longer. Such patients are even more likely to face either temporary or permanent reduced functional reserve, which typically further increases their healthcare resource use and the burden of care on their caregiver(s). Accordingly, these patients and their caregiver(s) may benefit from integrated supportive care provided via digitally supported interventions. This approach may either maintain or improve their quality of life, increase their independence, and optimize the healthcare resource use from early stages. ADLIFE is an EU-funded project, aiming to improve the quality of life of older people with ACD by providing integrated personalized care via a digitally enabled toolbox. Indeed, the ADLIFE toolbox is a digital solution which provides patients, caregivers, and health professionals with digitally enabled, integrated, and personalized care, supporting clinical decisions, and encouraging independence and self-management. Here we present the protocol of the ADLIFE study, which is designed to provide robust scientific evidence on the assessment of the effectiveness, socio-economic, implementation, and technology acceptance aspects of the ADLIFE intervention compared to the current standard of care (SoC) when applied in real-life settings of seven different pilot sites across six countries. A quasi-experimental trial following a multicenter, non-randomized, non-concurrent, unblinded, and controlled design will be implemented. Patients in the intervention group will receive the ADLIFE intervention, while patients in the control group will receive SoC. The assessment of the ADLIFE intervention will be conducted using a mixed-methods approach.
KW - advanced chronic disease
KW - chronic obstructive pulmonary disease
KW - digital health
KW - effectiveness
KW - evaluation
KW - heart failure
KW - implementation
KW - mixed-methods approach
KW - socio-economic impact
U2 - 10.3390/ijerph20043152
DO - 10.3390/ijerph20043152
M3 - Journal article
C2 - 36833849
AN - SCOPUS:85148964852
SN - 1661-7827
VL - 20
JO - International Journal of Environmental Research and Public Health
JF - International Journal of Environmental Research and Public Health
IS - 4
M1 - 3152
ER -